NASDAQ:TBPH Theravance Biopharma Q3 2025 Earnings Report $13.92 -0.07 (-0.50%) Closing price 10/13/2025 04:00 PM EasternExtended Trading$13.82 -0.10 (-0.75%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Theravance Biopharma EPS ResultsActual EPSN/AConsensus EPS -$0.03Beat/MissN/AOne Year Ago EPSN/ATheravance Biopharma Revenue ResultsActual RevenueN/AExpected Revenue$19.89 millionBeat/MissN/AYoY Revenue GrowthN/ATheravance Biopharma Announcement DetailsQuarterQ3 2025Date11/11/2025TimeBefore Market OpensConference Call DateTuesday, November 11, 2025Conference Call Time5:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Theravance Biopharma Earnings HeadlinesTheravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting2 hours ago | prnewswire.comAnalysts Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $23.00October 12 at 2:57 AM | americanbankingnews.comBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's preparing for a "mind blowing" new launch that could see Tesla move away from electric cars... and into a new market.October 14 at 2:00 AM | Altimetry (Ad)B. Riley Securities Initiates Coverage of Theravance Biopharma (TBPH) with Buy RecommendationSeptember 12, 2025 | msn.comTheravance Biopharma initiated with a Buy at B. RileySeptember 12, 2025 | msn.comTheravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | prnewswire.comSee More Theravance Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Theravance Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Theravance Biopharma and other key companies, straight to your email. Email Address About Theravance BiopharmaTheravance Biopharma (NASDAQ:TBPH) is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S. Food and Drug Administration for the maintenance treatment of chronic obstructive pulmonary disease (COPD). In addition to its marketed respiratory franchise, Theravance Biopharma maintains a diversified pipeline with clinical-stage programs in immunology and rare disease. Its immunology efforts include a gut-selective pan-JAK inhibitor being evaluated for inflammatory bowel diseases, while its rare disease portfolio features a norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension. The company leverages internal research capabilities alongside collaborations and partnerships to advance its small-molecule candidates through clinical and regulatory milestones. Founded in 1998 as part of a respiratory research group of GlaxoSmithKline and later spun out as an independent entity in 2014, Theravance Biopharma is headquartered in South San Francisco, California. It operates research facilities in the Bay Area and maintains corporate offices in Dublin, Ireland, supporting its global clinical programs. The company’s leadership team, under President and Chief Executive Officer Rick E. Winningham, brings deep expertise in pharmaceutical R&D, regulatory affairs and commercial strategy aimed at delivering new therapeutic options to patients worldwide.View Theravance Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi Deal Upcoming Earnings ASML (10/15/2025)Kinder Morgan (10/15/2025)Bank of America (10/15/2025)Prologis (10/15/2025)Abbott Laboratories (10/15/2025)Morgan Stanley (10/15/2025)The PNC Financial Services Group (10/15/2025)Progressive (10/15/2025)Interactive Brokers Group (10/16/2025)CSX (10/16/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
